Welcome by EY Basel, Biotech Sector Lead Switzerland, Basel Office Managing Partner – Gabriela Güntherodt

• Immitra Bio GmbH – Jan Nelis (CEO, Co-Chair) – Zurich/Genève, 01.2025

  The ETH spin-off Immitra Bio is developing a novel platform for scalable, curative in-vivo gene-editing therapies. Its unique approach combines CRISPR and lipid nanoparticles to activate dormant backup genes by inserting small activating DNA elements into promoters, thereby compensating for defective genes and addressing the root cause of rare genetic disorders in hematology and CNS.

• Hemastatx GmbH – Kevin Hollevoet, PhD (CEO, Chair) – Allschwil, 02.2025

  Hemastatx is a KU Leuven spin-off and BaseLaunch portfolio company with HQ in Switzerland and R&D activities in Belgium. Its lead program is a first-in-class anti-ADAMTS13 antibody designed to address severe bleeding in patients suffering from von Willebrand factor-related disorders.
  
  

• Scanvio Medical AG – Stefan Tuchschmid, PhD (CEO, Chair) – Zurich, 05.2024

  The ETH AI Center spin-off Scanvio Medical is developing an AI-powered platform that transforms standard ultrasound devices into intelligent diagnostic systems for gynecology. Its real-time guidance and detection software supports clinicians to improve the detection and mapping of endometriosis, a disease affecting more than 200 million women worldwide. By augmenting clinical expertise, Scanvio aims to dramatically shorten the diagnostic delay and enable earlier, more accurate treatment decisions.
  
  

• Tolremo Therapeutics AG – Stefanie Flückiger-Mangual, PhD (CEO) – Basel, 03.2017

  Clinical stage company with a mission to prevent non-genetic resistance development to cancer therapies. Its lead asset TT125-802, a small molecule CBP/p300 bromodomain inhibitor, demonstrated best-in-class safety and efficacy in a first-in-human cancer study. FDA Fast Track Designation was received for treatment of two types of lung cancer. Currently, it is advancing its asset as monotherapy and in combination with targeted agents in lung cancer and hematological malignancies to provide more durable treatment to patients in need.